跳至主要内容
临床试验/NCT01618188
NCT01618188已完成1 期

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2012年6月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
52
试验地点
1
主要终点
Area under the glucose infusion rate curve

研究概览

简要总结

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic properties (the effect of the investigated drug on the body) of NN1218 in subjects with type 1 diabetes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes mellitus for more than 12 months
  • Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion for more than 12 months
  • Body mass index (BMI) between 18.0-28.0 kg/m^2 (both inclusive)

排除标准

  • Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to trial start
  • Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
  • Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

研究组 & 干预措施

Formulation A

Experimental

干预措施: Faster-acting insulin aspart (Drug)

Formulation B

Experimental

干预措施: Faster-acting insulin aspart (Drug)

Insulin Aspart

Active Comparator

干预措施: insulin aspart (Drug)

结局指标

主要结局

Area under the glucose infusion rate curve

时间窗: From 0 to 2 hours

次要结局

  • Area under the glucose infusion rate curve(From 0 to 12 hours)
  • Maximum glucose infusion rate(Within 0 to 12 hours after dosing)
  • Time to maximum glucose infusion rate(Within 0 to 12 hours after dosing)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验